ArticleInternational urology and nephrology2025
Analysis of gray zone PSA and PSAD correlated with PIRADS v2.1 in the MRI-US fusion prostate biopsy era: a retrospective bi-centre study.
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnostic and Clinical Impact of Imaging Modality on PSA Density: TRUS Versus MRI in Gray-Zone Prostate Cancer.Current oncology (Toronto, Ont.) · 2026Article
- Urinary Epithelial Cell Adhesion Molecule (EpCAM) as a Noninvasive Biomarker for Detecting Clinically Significant Prostate Cancer in Men With Equivocal PSA Levels.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple parameters including PSA, PSAD, and PIRADS v2.1 score, are being associated in an effort to increase the overall detection rate of clinically significant prostate cancer (csPCa). This study aims to explore gray zone PSA and PSAD correlated with PIRADS score in the detection of csPCa using MRI-US fusion prostate biopsy.
methodsMen with PSA of 4-10 who underwent prostate multiparametric MRI of the prostate (mpMRI) were divided into two groups (4-< 7 and ≥ 7-10 ng/mL) and according to PSA density (< 0.10, 0.10-0.20 and > 0.20). Subgroups according to PIRADS score were made for each group. Chi-square test was utilized for analysing the comparison of histopathology results between the PSA and PSA density subgroups per PIRADS lesion category. Using receiver-operating characteristic (ROC) curves, the diagnostic accuracy of PSA and PSAD in identifying csPCa were evaluated, and the best cutoff values were identified.
resultsOverall detection rate of csPCa was 40.4% (146/361) in the cohort of men with gray zone PSA value. Clinically significant difference in csPCa detection rate was observed in the PSAD subgroups (p = < 0.001) while no significant difference was observed in the two groups of PSA (p = 0.387). On subgroup analysis, only the PSAD subcategories of PIRADS 4 and 5 showed significant difference (p = 0.028 and p = 0.003, respectively). Based on the ROC curve, the optimal cutoff for PSA was 6.32 with sensitivity and specificity of 65.1% and 43.3%, respectively [AUC 0.54 (0.48-0.60)]. PSAD optimal cutoff was 0.139 with sensitivity and specificity of 80.8% and 49.3%, respectively [AUC 0.67 (0.61-0.72)].
conclusionsPSA and PSAD combined with PIRADS v2.1 provide more diagnostic value than when used alone and can be used to counsel men who will undergo MRI-US fusion biopsy. In the gray zone, PSAD is a more reliable diagnostic predictor of csPCa than PSA.
Indexed as
Identifiers
40341963What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.